Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies
Version of Record online: 29 OCT 2011
Copyright © 2011 Crohn's & Colitis Foundation of America, Inc.
Inflammatory Bowel Diseases
Volume 18, Issue 9, pages 1628–1633, September 2012
How to Cite
Kopylov, U., Mazor, Y., Yavzori, M., Fudim, E., Katz, L., Coscas, D., Picard, O., Chowers, Y., Eliakim, R. and Ben-Horin, S. (2012), Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies. Inflamm Bowel Dis, 18: 1628–1633. doi: 10.1002/ibd.21919
- Issue online: 9 AUG 2012
- Version of Record online: 29 OCT 2011
- Manuscript Accepted: 15 SEP 2011
- Manuscript Received: 27 AUG 2011
Options for accessing this content:
- If you are a society or association member and require assistance with obtaining online access instructions please contact our Journal Customer Services team.
- If your institution does not currently subscribe to this content, please recommend the title to your librarian.
- Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
Login via OpenAthens
Search for your institution's name below to login via Shibboleth.
Registered Users please login:
- Access your saved publications, articles and searches
- Manage your email alerts, orders and subscriptions
- Change your contact information, including your password
Please register to:
- Save publications, articles and searches
- Get email alerts
- Get all the benefits mentioned below!